MA55064A - Composés utilisés comme inhibiteurs de kinase - Google Patents

Composés utilisés comme inhibiteurs de kinase

Info

Publication number: MA55064A
Authority: MA; Morocco
Prior art keywords: kinase inhibitors; compounds used; compounds; kinase; inhibitors
Prior art date: 2015-12-16

Application number

MA055064A

Other languages

English (en)

Inventor

Nicolas Guisot

Original Assignee

Loxo Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-16

Filing date

2016-12-16

Publication date

2021-09-29

2015-12-16 Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en

2016-08-15 Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en

2016-12-16 Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc

2021-09-29 Publication of MA55064A publication Critical patent/MA55064A/fr

Links

150000001875 compounds Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

MA055064A 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase MA55064A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1522245.8A GB201522245D0 (en)	2015-12-16	2015-12-16	Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en)	2016-08-15	2016-08-15	Compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
MA55064A true MA55064A (fr)	2021-09-29

Family

ID=57590725

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA49809A MA49809A1 (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase
MA055064A MA55064A (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA49809A MA49809A1 (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase

Country Status (38)

Country	Link
US (8)	US10695323B2 (fr)
EP (2)	EP3390395B1 (fr)
JP (3)	JP6731483B2 (fr)
KR (2)	KR20210018530A (fr)
CN (9)	CN114573510B (fr)
AU (4)	AU2016373530B2 (fr)
CA (1)	CA3008488C (fr)
CL (1)	CL2018001591A1 (fr)
CO (1)	CO2018006164A2 (fr)
CR (1)	CR20180367A (fr)
CY (2)	CY1123561T1 (fr)
DK (1)	DK3390395T3 (fr)
EA (1)	EA035132B1 (fr)
ES (2)	ES2828431T3 (fr)
FI (1)	FIC20240004I1 (fr)
FR (1)	FR24C1009I2 (fr)
HR (1)	HRP20201835T1 (fr)
HU (2)	HUE051921T2 (fr)
IL (4)	IL285976B2 (fr)
LT (2)	LT3390395T (fr)
LU (1)	LUC00330I2 (fr)
MA (2)	MA49809A1 (fr)
MD (1)	MD3390395T2 (fr)
MX (2)	MX394193B (fr)
MY (2)	MY202026A (fr)
NL (1)	NL301262I2 (fr)
NO (1)	NO2024008I1 (fr)
NZ (1)	NZ743553A (fr)
PE (3)	PE20220502A1 (fr)
PH (1)	PH12018501268A1 (fr)
PT (1)	PT3390395T (fr)
RS (1)	RS60982B9 (fr)
SG (2)	SG11201805044WA (fr)
SI (1)	SI3390395T1 (fr)
TN (1)	TN2018000213A1 (fr)
UA (2)	UA122258C2 (fr)
WO (1)	WO2017103611A1 (fr)
ZA (5)	ZA201804137B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
CN114685516A (zh)	2015-09-16	2022-07-01	洛克索肿瘤学股份有限公司	用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
ES2828431T3 (es)	2015-12-16	2021-05-26	Loxo Oncology Inc	Compuestos útiles como inhibidores de cinasa
GB201801226D0 (en)	2018-01-25	2018-03-14	Redx Pharma Plc	Modulators of Rho-associated protein kinase
EP3774782A2 (fr) *	2018-04-06	2021-02-17	Black Belt TX Ltd	Inhibiteurs d'atf6 et leurs utilisations
WO2019220962A1 (fr) *	2018-05-18	2019-11-21	富士フイルム株式会社	Procédé de production d'un composé 3-difluorométhylpyrazole, procédé de production d'un composé d'acide 3-difluorométhylpyrazole-4-carboxylique, et composé de pyrazolidine
CA3224985C (fr) *	2018-07-31	2025-11-18	Loxo Oncology, Inc.	Dispersions séchées par pulvérisation, formulations et polymorphies de (s)-5-amino-3-(4-((5-fluoro-2-méthoxybenzamido)méthyle)phényle)(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
WO2021028645A1 (fr)	2019-08-09	2021-02-18	Kalvista Pharmaceuticals Limited	Inhibiteurs de la kallicréine plasmatique
WO2021053234A1 (fr) *	2019-09-19	2021-03-25	Johann Wolfgang Goethe-Universität Frankfurt am Main	Composés et compositions pour le traitement d'une maladie rénale
CN110724135B (zh) *	2019-11-18	2023-04-28	上海医药工业研究院有限公司	一种艾拉普林中间体及其制备方法
JP7142173B2 (ja) *	2019-12-06	2022-09-26	ロクソオンコロジー，インコーポレイテッド	ブルトン型チロシンキナーゼ阻害剤の投薬
MX2022008148A (es)	2020-01-02	2022-07-21	Dizal Jiangsu Pharmaceutical Co Ltd	Inhibidores de btk.
EP4118086A1 (fr) *	2020-03-12	2023-01-18	Fochon Biosciences, Ltd.	Composés utiles en tant qu'inhibiteurs de kinase
TWI809489B (zh) *	2020-09-10	2023-07-21	美商絡速藥業公司	用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) *	2020-10-15	2022-03-15	天津济坤医药科技有限公司	泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN116348453B (zh) *	2021-04-25	2025-07-04	烨辉医药科技(上海)有限公司	杂芳族甲酰胺化合物及其用途
CN117320712A (zh)	2021-05-14	2023-12-29	罗索肿瘤学公司	布鲁顿酪氨酸激酶抑制剂的共晶型
CA3223769A1 (fr) *	2021-07-01	2023-01-05	Xinglu ZHOU	Tyrosine kinase de bruton et agent de degradation mutant, composition et utilisation associees
WO2023284765A1 (fr) *	2021-07-16	2023-01-19	深圳市塔吉瑞生物医药有限公司	Composé pyrazole substitué, composition le contenant et son utilisation
KR20240157639A (ko)	2021-12-14	2024-11-01	크로스파이어 온콜로지 홀딩 비.브이.	거대고리 btk 억제제
WO2023143355A1 (fr) *	2022-01-28	2023-08-03	Hansoh Bio Llc	Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales
EP4474377A4 (fr) *	2022-03-03	2025-07-30	Shenzhen Targetrx Inc	Composé hétéroaryle substitué par cycloalkyle ou hétérocyclyle, composition et utilisation de celui-ci
US20250188094A1 (en) *	2022-03-18	2025-06-12	Insilico Medicine Ip Limited	Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376B (zh) *	2022-12-15	2025-05-16	南京雷正医药科技有限公司	一种芳香族酰胺类化合物、药物组合物及其用途
WO2024176164A1 (fr)	2023-02-22	2024-08-29	Assia Chemical Industries Ltd.	Forme à l'état solide de pirtobrutinib
WO2024245578A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique
WO2024246287A1 (fr)	2023-06-02	2024-12-05	Crossfire Oncology Holding B.V.	Utilisation médicale d'un inhibiteur de btk réversible macrocyclique
WO2024245577A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk
WO2024256574A1 (fr)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Procédé de préparation d'inhibiteurs de btk macrocycliques
WO2024256568A1 (fr)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Formes salines et formes cristallines d'un inhibiteur de btk macrocyclique
KR20250046558A (ko)	2023-09-27	2025-04-03	임창섭	5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
TW202532067A (zh) *	2023-12-13	2025-08-16	大陸商正大天晴藥業集團股份有限公司	含有吡唑環及雙環雜芳基的化合物
WO2025137329A1 (fr) *	2023-12-22	2025-06-26	Neupharma, Inc	Entités chimiques particulières, compositions et procédés
CN119059974B (zh) *	2024-08-12	2025-10-28	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的制备方法
CN119059973A (zh) *	2024-08-12	2024-12-03	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的合成工艺
CN120504661B (zh) *	2025-07-14	2025-11-07	复旦大学	Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko)	1999-09-17	2002-11-27	애보트 게엠베하 운트 콤파니 카게	치료제로서의 피라졸로피리미딘
US6291504B1 (en) *	1999-10-20	2001-09-18	Dupont Pharmaceuticals Company	Acylsemicarbazides and their uses
US20030225098A1 (en)	2002-03-21	2003-12-04	Hirst Gavin C.	Kinase inhibitors
PL2526933T3 (pl)	2006-09-22	2015-08-31	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej Brutona
MX2009003650A (es) *	2006-10-06	2009-04-22	Abbott Lab	Nuevos imidazotiazoles e imidazoxazoles.
ES2403546T3 (es)	2006-11-03	2013-05-20	Pharmacyclics, Inc.	Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
SG10201508035TA (en)	2007-03-28	2015-10-29	Pharmacyclics Inc	Inhibitors of bruton's tyrosine kinase
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en)	2008-06-27	2015-02-27	Celgene Avilomics Res Inc	Pyrimidine based compound and uses thereof
CA2730930C (fr)	2008-07-16	2015-01-13	Pharmacyclics, Inc.	Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
PL2324008T3 (pl) *	2008-07-24	2012-09-28	Nerviano Medical Sciences Srl	3,4-diarylopirazole jako inhibitory kinazy białkowej
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
US7741330B1 (en)	2009-10-12	2010-06-22	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
NZ772688A (en)	2010-06-03	2022-09-30	Pharmacyclics Llc	The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012003405A1 (fr) *	2010-06-30	2012-01-05	Ironwood Pharmaceuticals, Inc.	Stimulateurs de sgc
EA025496B1 (ru)	2011-05-17	2016-12-30	Принсипиа Биофарма Инк.	Ингибиторы тирозинкиназы
HUE048834T2 (hu)	2011-05-17	2020-08-28	Univ California	Kináz inhibitorok
EA201490265A1 (ru)	2011-07-13	2014-12-30	Фармасайкликс, Инк.	Ингибиторы тирозинкиназы брутона
EP2548877A1 (fr)	2011-07-19	2013-01-23	MSD Oss B.V.	Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK2861599T3 (da)	2012-06-18	2020-03-02	Principia Biopharma Inc	Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
WO2014022569A1 (fr)	2012-08-03	2014-02-06	Principia Biopharma Inc.	Traitement de la sécheresse oculaire
MA37830B1 (fr) *	2012-08-10	2018-09-28	Boehringer Ingelheim Int	Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
GB201214750D0 (en) *	2012-08-17	2012-10-03	Respivert Ltd	Compounds
CN105008344B (zh) *	2012-11-02	2017-07-25	辉瑞公司	布鲁顿氏酪氨酸激酶抑制剂
CN103848810A (zh) *	2012-11-30	2014-06-11	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
US8957080B2 (en)	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
GB201309085D0 (en)	2013-05-20	2013-07-03	Redx Pharma Ltd	Compounds
RS60934B1 (sr) *	2013-09-30	2020-11-30	Guangzhou Innocare Pharma Tech Co Ltd	Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
WO2015075051A1 (fr) *	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Inhibiteurs allostériques de protéines kinases c atypiques
EP3082809B1 (fr)	2013-12-20	2021-01-20	Merck Sharp & Dohme Corp.	Inhibiteurs de btk
EP4681737A3 (fr)	2014-02-21	2026-03-11	Principia Biopharma Inc.	Sels et forme solide d'un inhibiteur de btk
GB201404987D0 (en)	2014-03-20	2014-05-07	Redx Pharma Ltd	Compounds
CN105085474B (zh) *	2014-05-07	2018-05-18	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) *	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
AU2016212230B2 (en)	2015-01-28	2019-09-19	Bayer Pharma Aktiengesellschaft	4H-pyrrolo[3,2-c]pyridin-4-one derivatives
GB2548542A (en) *	2015-06-16	2017-09-27	Redx Pharma Plc	Compounds
JOP20160198B1 (ar)	2015-09-16	2022-03-14	Janssen Pharmaceuticals Inc	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar)	2015-09-16	2020-08-27	Katholieke Univ Leuven Ku Leuven Research & Development	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN114685516A (zh)	2015-09-16	2022-07-01	洛克索肿瘤学股份有限公司	用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
CA3008648C (fr)	2015-12-16	2023-01-10	Priostar Pty Ltd	Dendrimere et formulations de ceux-ci
US10737302B2 (en)	2015-12-16	2020-08-11	Ecolab Usa Inc.	Peroxyformic acid compositions for membrane filtration cleaning
ES2828431T3 (es)	2015-12-16	2021-05-26	Loxo Oncology Inc	Compuestos útiles como inhibidores de cinasa
ES2854733T3 (es)	2015-12-16	2021-09-22	Bristol Myers Squibb Co	Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
PE20181074A1 (es)	2015-12-16	2018-07-04	Boehringer Ingelheim Int	Compuestos heteroaromaticos como inhibidores de btk

2016
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/fr active Active
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510B/zh active Active
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/fr not_active Ceased
- 2016-12-16 CN CN202210310724.0A patent/CN114716381B/zh active Active
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 MX MX2021003478A patent/MX394193B/es unknown
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko not_active Withdrawn
- 2016-12-16 MY MYPI2022003989A patent/MY202026A/en unknown
- 2016-12-16 CN CN202111022488.4A patent/CN113603645B/zh active Active
- 2016-12-16 ES ES20194724T patent/ES3041897T3/es active Active
- 2016-12-16 CN CN202210311995.8A patent/CN114634447B/zh active Active
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 CN CN202210312064.XA patent/CN114605327B/zh active Active
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 RS RS20201291A patent/RS60982B9/sr unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 EP EP20194724.9A patent/EP3782994B1/fr active Active
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 CN CN202210312050.8A patent/CN114591242B/zh active Active
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active Active
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 MY MYPI2022003990A patent/MY200590A/en unknown
- 2016-12-16 MX MX2018007267A patent/MX380907B/es unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/fr active Active
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 CN CN202111022492.0A patent/CN113636978B/zh active Active
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-05-28 ZA ZA2020/03176A patent/ZA202003176B/en unknown
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
2023
- 2023-07-31 US US18/362,249 patent/US12220401B2/en active Active
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-02-29 LU LU00330C patent/LUC00330I2/fr unknown
- 2024-02-29 NO NO2024008C patent/NO2024008I1/no unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I2/fr active Active
- 2024-03-04 CY CY2024003C patent/CY2024003I1/el unknown
- 2024-03-06 LT LTPA2024506C patent/LTPA2024506I1/lt unknown
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
- 2024-11-21 US US18/955,844 patent/US20250090500A1/en active Pending

Also Published As

Publication number	Publication date
AU2016373530A1 (en)	2018-07-05
NZ743553A (en)	2022-08-26
US10918622B2 (en)	2021-02-16
US20250090500A1 (en)	2025-03-20
CN113603645B (zh)	2024-10-29
KR20210018530A (ko)	2021-02-17
KR102215792B1 (ko)	2021-02-16
IL285976A (en)	2021-10-31
FIC20240004I1 (fi)	2024-03-01
MX394193B (es)	2025-03-21
PE20220502A1 (es)	2022-04-07
CA3008488C (fr)	2023-10-10
JP2018538307A (ja)	2018-12-27
CN114634447A (zh)	2022-06-17
ZA202107471B (en)	2023-03-29
CN113636978B (zh)	2024-10-29
FR24C1009I2 (fr)	2025-02-07
EA035132B1 (ru)	2020-04-30
JP2020172535A (ja)	2020-10-22
KR20180115261A (ko)	2018-10-22
AU2021225162A1 (en)	2021-09-30
DK3390395T3 (da)	2020-09-28
EP3782994A1 (fr)	2021-02-24
ES3041897T3 (en)	2025-11-17
FR24C1009I1 (fr)	2024-05-24
LT3390395T (lt)	2020-11-25
NO2024008I1 (no)	2024-02-29
SI3390395T1 (sl)	2020-11-30
UA122258C2 (uk)	2020-10-12
SG10202012498TA (en)	2021-01-28
US20210093611A1 (en)	2021-04-01
CN108473481A (zh)	2018-08-31
IL276283B (en)	2021-03-25
ZA202100544B (en)	2023-06-28
MY202026A (en)	2024-03-29
CN114634447B (zh)	2024-11-15
MY200590A (en)	2024-01-04
WO2017103611A1 (fr)	2017-06-22
US10342780B2 (en)	2019-07-09
CN113636978A (zh)	2021-11-12
US10464905B2 (en)	2019-11-05
CN113603645A (zh)	2021-11-05
PE20181449A1 (es)	2018-09-12
IL259923B (en)	2020-08-31
EP3390395B1 (fr)	2020-09-09
IL285976B1 (en)	2023-06-01
HUS2400003I1 (hu)	2024-03-28
JP7086140B2 (ja)	2022-06-17
SG11201805044WA (en)	2018-07-30
BR112018012341A2 (pt)	2018-12-04
PT3390395T (pt)	2020-11-03
US10695323B2 (en)	2020-06-30
AU2021225161A1 (en)	2021-09-30
EP3390395A1 (fr)	2018-10-24
CO2018006164A2 (es)	2018-09-20
AU2021225162B2 (en)	2023-08-03
ZA202003176B (en)	2026-03-25
PE20220507A1 (es)	2022-04-07
CN114716381B (zh)	2025-03-11
CA3008488A1 (fr)	2017-06-22
TN2018000213A1 (en)	2019-10-04
CY2024003I2 (el)	2024-09-20
CN114591242A (zh)	2022-06-07
US20190000806A1 (en)	2019-01-03
US20190135762A1 (en)	2019-05-09
LUC00330I2 (fr)	2026-03-04
HUE051921T2 (hu)	2021-03-29
EA201891268A1 (ru)	2018-11-30
ES2828431T3 (es)	2021-05-26
MX2021003478A (es)	2022-07-25
MD3390395T2 (ro)	2021-02-28
RS60982B1 (sr)	2020-11-30
AU2021225161B2 (en)	2023-08-03
AU2021201811B2 (en)	2022-01-27
CN108473481B (zh)	2022-04-19
RS60982B9 (sr)	2025-07-31
ZA202107472B (en)	2023-03-29
CR20180367A (es)	2018-11-12
AU2021201811A1 (en)	2021-04-22
US20200276162A1 (en)	2020-09-03
IL281067B (en)	2022-04-01
US12220401B2 (en)	2025-02-11
HK1263254A1 (en)	2020-02-21
IL281067A (en)	2021-04-29
CN114716381A (zh)	2022-07-08
CN114573510B (zh)	2025-02-25
JP2022120013A (ja)	2022-08-17
CN114605327B (zh)	2025-03-11
CN114621146A (zh)	2022-06-14
CN114573510A (zh)	2022-06-03
CN114605327A (zh)	2022-06-10
AU2016373530B2 (en)	2021-01-21
US11471441B2 (en)	2022-10-18
CY2024003I1 (el)	2024-09-20
US20180362512A1 (en)	2018-12-20
UA127863C2 (uk)	2024-01-31
US20230372298A1 (en)	2023-11-23
IL259923A (en)	2018-07-31
MX380907B (es)	2025-03-12
CL2018001591A1 (es)	2018-09-28
ZA201804137B (en)	2022-08-31
IL285976B2 (en)	2023-10-01
CY1123561T1 (el)	2022-03-24
EP3782994B1 (fr)	2025-07-16
MA49809A1 (fr)	2021-08-31
CN114591242B (zh)	2025-01-07
NL301262I2 (nl)	2024-04-24
JP7419437B2 (ja)	2024-01-22
HRP20201835T1 (hr)	2021-01-08
IL276283A (en)	2020-09-30
LTPA2024506I1 (fr)	2024-03-25
JP6731483B2 (ja)	2020-07-29
MX2018007267A (es)	2018-11-09
US11826351B2 (en)	2023-11-28
PH12018501268A1 (en)	2019-02-18
US20220062239A1 (en)	2022-03-03

Publication	Publication Date	Title
FR24C1009I2 (fr)	2025-02-07	Composés utilisés comme inhibiteurs de kinase
MA52119A (fr)	2018-08-29	Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr)	2021-04-28	Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr)	2019-05-22	Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr)	2019-03-13	Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr)	2021-06-02	Composés hétérocycliques comme immunomodulateurs
EP3720430A4 (fr)	2021-05-05	Composés benzocarbonyle
EP3691623A4 (fr)	2021-05-26	Composés de benzosulfonyle
MA51229A (fr)	2021-03-24	Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA42923A (fr)	2021-04-28	Composés bicycliques comme inhibiteurs mixtes de atx/ca
DK3303348T3 (da)	2019-11-11	Naphthyridinforbindelser som JAK-kinaseinhibitorer
MA41677A (fr)	2021-06-02	Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
EP3337787A4 (fr)	2019-05-08	Composés pyrazolo hétérocycliques condensés comme inhibiteurs d'erk
EP3397629A4 (fr)	2019-06-05	Composés inhibiteurs de métallo-enzymes
DK3717488T3 (da)	2021-12-13	Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
EP3319966A4 (fr)	2019-01-09	Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
MA41803A (fr)	2018-01-30	Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
EP3728289A4 (fr)	2021-10-13	Composés optimisés
EP3464336A4 (fr)	2020-01-15	Composés
EP3638237A4 (fr)	2021-01-13	Composés aminothiazoles utilisés comme inhibiteurs de protéine kinase
EP3310352A4 (fr)	2019-03-13	Composés cristallins
PT3552017T (pt)	2022-05-04	Compostos úteis como inibidores de ripk1
EP3717483A4 (fr)	2021-07-14	Composés de pyrazolopyridinone
EP3713941A4 (fr)	2021-04-14	Composés de pyrazolopyridinone
MA48946A (fr)	2020-04-08	Composés